stocks logo

OKUR

Onkure Therapeutics Inc
$
3.130
-0.760(-19.540%)
  • Overview
  • Forecast
  • Valuation
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.680
Open
3.680
VWAP
3.32
Vol
309.49K
Mkt Cap
42.05M
Low
3.050
Amount
1.03M
EV/EBITDA(TTM)
--
Total Shares
13.44M
EV
-52.99M
EV/OCF(TTM)
--
P/S(TTM)
--

OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved ...Show More

4 Analyst Rating
up Image
914.38% Upside
Wall Street analysts forecast OKUR stock price to riseover the next 12 months. According to Wall Street analysts, the average 1-year price target for OKUR is 31.75USD with a low forecast of30.00USD and a high forecast of34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
up Image
914.38% Upside
Current: 3.130
sliders
Low
30.00
Averages
31.75
High
34.00
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$40 → $34
2025-03-18
Reason
Oppenheimer
Matt Biegler
Buy
Maintains
$35 → $30
2025-03-11
Reason
Oppenheimer lowered the firm's price target on OnKure Therapeutics to $30 from $35 but keeps an Outperform rating on the shares after its Q4 results. The firm's post-earnings discussion with the company revealed that an important update from PIKture-01 is slated for the second half of 2025 and should provide enough data to make a determination on OKI-219's competitive profile relative to RLY-2608 and STX-478, the analyst tells investors in a research note. While OKI-219 is ultra-selective for common H1047R mutant, the company is also being more vocal about its pan-mutant inhibitor pipeline, the firm adds.
Jones Trading
Soumit Roy
Strong Buy
Initiates
$32
2025-01-28
Reason
JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology company is developing targeted PI3Kalpha inhibitors for the treatment of breast cancer and other solid tumors with mutations in the PIK3CA gene, notes the analyst, who points out that this space has come under spotlight recently following the acquisition of Scorpion Therapeutics by Eli Lilly (LLY) in January for up to $2.5B. OnKure's lead asset, OKI-219, is a small molecule point-mutation specific inhibitor that targets PI3Kalpha harboring a H1047R mutation, notes the analyst, who adds that OKI-219 has "the potential to be the first approved mutation-specific PI3Kalpha inhibitor."
Leerink Partners
Andrew Berens
Buy
Initiates
$33
2024-12-05
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$40
2024-11-08
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Initiates
$40
2024-10-17
Reason
Oppenheimer
Matt Biegler
Buy
Initiates
$35
2024-10-10
Reason

Valuation Metrics

The current forward P/E ratio for Onkure Therapeutics Inc(OKUR.O) is -0.61, compared to its 5-year average forward P/E of -2.78. For a more detailed relative valuation and DCF analysis to assess Onkure Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.78
Current PE
-0.61
Overvalued PE
-0.56
Undervalued PE
-5.01

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
33.94
Current PS
104.53
Overvalued PS
97.22
Undervalued PS
-29.35

Financials

Annual
Quarterly
FY2024Q3
YoY :
-77.67%
-4.66M
Operating Profit
FY2024Q3
YoY :
-80.77%
-3.69M
Net Income after Tax
FY2024Q3
YoY :
+94.37%
-11.04
EPS - Diluted
FY2024Q3
YoY :
-87.86%
-2.28M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
8.2M
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
4.5M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

OKUR News & Events

Events Timeline
2025-03-10 (ET)
2025-03-10
20:49:22
OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)
select
2024-12-10 (ET)
2024-12-10
06:04:28
OnKure Therapeutics announces safety, pharmacokinetic data on OKI-219
select
2024-10-23 (ET)
2024-10-23
17:05:23
OnKure files to sell 2.94M shares of Class A common stock for holders
select
News
6.0
03-11Benzinga
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
4.0
03-10Business Insider
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)
9.5
03-10Newsfilter
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
4.0
01-28Benzinga
Jones Trading Initiates Coverage On OnKure Therapeutics with Buy Rating, Announces Price Target of $32
6.5
2024-12-10Business Insider
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
9.0
2024-12-10Business Insider
OnKure Therapeutics Reports Positive Preliminary Data From First-in-human Study Of OKI-219
9.0
2024-12-10Newsfilter
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
8.5
2024-11-26Business Insider
OnKure Therapeutics Reports Strategic Merger and Financial Updates
2.0
2024-11-25Newsfilter
OnKure Announces New Date for Upcoming Investor Call
8.5
2024-11-09Business Insider
OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth
1.0
2024-11-05Newsfilter
OnKure to Present at the Stifel 2024 Healthcare Conference
4.0
2024-10-17Benzinga
HC Wainwright & Co. Assumes OnKure Therapeutics at Buy, Announces Price Target of $40
8.5
2024-10-10Benzinga
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm
4.0
2024-10-10Benzinga
This Builders FirstSource Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

FAQ

arrow icon

What is Onkure Therapeutics Inc (OKUR) stock price today?

The current price of OKUR is 3.13 USD — it hasdecreased-19.54 % in the last trading day.

arrow icon

What is Onkure Therapeutics Inc (OKUR)'s business?

arrow icon

What is the price predicton of OKUR Stock?

arrow icon

What is Onkure Therapeutics Inc (OKUR)'s revenue for the last quarter?

arrow icon

What is Onkure Therapeutics Inc (OKUR)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Onkure Therapeutics Inc (OKUR)'s fundamentals?

arrow icon

How many employees does Onkure Therapeutics Inc (OKUR). have?

arrow icon

What is Onkure Therapeutics Inc (OKUR) market cap?